DeciBio Consulting, LLC has acquired ownership of the Emmes Molecular Diagnostics (MDx) Infectious Disease Database and the Oncology Database from The Emmes Group Inc., effective January 1, 2020. These acquisitions are positioned to strengthen and expand the solutions DeciBio offers its clients.

The Emmes MDx (ID) Database has established itself as a unique and essential source of in-depth customer-level metrics, insights, and data for the most relevant molecular diagnostic tests and test panels across 1,000 MDx testing labs in the United States. Manufacturers use Emmes' MDx (ID) Database to support the following business functions:

- Sales profiling accounts, prioritizing accounts

Strategic marketing assessing instrument and assay manufacturer share shifts, assessing adoption of new assays

- Business development assessing winners/loser by customer type, understanding competitive dynamics

The Emmes Oncology Database offers similar customer-level information focused on tissue-based testing in 300 anatomic pathology, molecular oncology, and genetics labs in the United States.

We couldn't be more excited to bring the Emmes Databases into the DeciBio portfolio of market intelligence offerings, says DeciBio founding partner David Cavanaugh. We've seen and experienced first-hand how useful these databases are in understanding and assessing molecular diagnostic testing actions and decisions at the user level.

As part of the acquisition agreement, DeciBio will take over the product development, sales, and marketing activities for the Databases. The Emmes Group will support DeciBio in these activities, as well as with data collection.

DeciBio's industry knowledge, expertise, and polished skills coupled with its dedication to client needs and superior service make them the ideal partner, complementing the essence of our Company and successor to the legacy of our MDx Databases, says Edward Weiner...

To continue reading